Status:
COMPLETED
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
Lead Sponsor:
Emory University
Conditions:
Hurler Syndrome
Fanconi Anemia
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE1
Brief Summary
This is a single arm, phase I study to assess the tolerability of abatacept when combined with cyclosporine and mycophenolate mofetil as graft versus host disease prophylaxis in children undergoing un...
Detailed Description
Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only viable cure for children who suffer from a wide variety of rare, serious non-malignant diseases, such as Fanconi Anemia, H...
Eligibility Criteria
Inclusion
- Must be between the ages of 0-21 years at the time of admission for transplant.
- Must have one of the following diseases:
- Glanzmann thrombasthenia
- Wiskott-Aldrich syndrome or other combined immune deficiency
- Chronic-granulomatous disease
- Severe congenital neutropenia (with resistance to granulocyte-colony stimulating factor (GCSF) or chronic requirement of GCSF doses ≥10 mcg/kg)
- Leukocyte adhesion deficiency
- Shwachman-Diamond syndrome
- Diamond-Blackfan anemia ((transfusion dependent, including steroid failure or inability to wean steroids)
- Thalassemia major
- Fanconi anemia
- Hemophagocytic lymphohistiocytosis (inherited or acquired refractory to therapy or with recurrent episodes of hyperinflammation)
- Dyskeratosis-congenita
- Hurler Syndrome
- Chediak-Higashi syndrome
- Acquired (immune; non-inherited, non-congenital) severe aplastic anemia
- Sickle cell disease (SCD) (Hgb SS or S-Beta 0 thalassemia) will be eligible between ages 3 and 9.99 and with severe disease.
- Other inherited or congenital marrow failure syndromes complicated by severe aplastic anemia
- Other inherited or congenital red blood cell disorders requiring monthly chronic transfusion therapy.
- Congenital platelet disorders requiring frequent platelet transfusions (patient must have received at least 10 transfusions in the last 3 years).
- Other inherited or congenital granulocyte disorders resulting in at least three inpatient hospitalizations in the past three years for infection.
- Must have an unrelated adult donor (marrow or PBSC) who is at least a 7/8 match (A, B, C, DRB1; the mismatch can be at an allele or antigen level) or an unrelated cord blood unit that is matched at least seven of eight loci (A, B and C antigen level-DRB1 allele level) and provides a minimum pre-cryopreservation total nucleated cell (TNC) dose of 7.5 x 107 TNC/kg recipient weight. Mismatches at the DRB1 locus may be at an antigen or allele level.
Exclusion
- Human leukocyte antigen (HLA) matched related donor.
- Severe combined immune deficiency.
- Bridging (portal to portal) fibrosis or cirrhosis of the liver.
- Pulmonary: diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin), forced expiratory volume (FEV1) or forced vital capacity (FVC) \< 40% of predicted. In child unable to perform pulmonary function testing, a chronic need for supplemental oxygen will serve as the exclusionary criterion.
- Severe renal dysfunction defined as estimated glomerular filtration rate (GFR) of \<60 ml/min/1.73m2.
- Severe cardiac dysfunction defined as shortening fraction \< 25%.
- Neurologic impairment other than hemiplegia, defined as full-scale intelligence quotient (IQ) less than or equal to 70, quadriplegia or paraplegia, inability to ambulate, or any impairment resulting in decline of Lansky performance score to \< 70%.
- Clinical stroke within 6 months of anticipated transplant.
- Karnofsky or Lansky functional performance score \< 50%
- HIV infection.
- Uncontrolled viral, bacterial, fungal or protozoal infection at the time of study enrollment.
- Patient with unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate bone marrow transplantation.
- Patient or patient's guardian(s) unable to understand the nature and risks inherent in the blood and marrow transplant process.
- History of non-compliance severe enough in the estimation of the treating team to preclude the patient from undergoing unrelated donor transplantation.
- Patient is pregnant or lactating
- Patients HLA antibody testing demonstrates an antibody directed against a disparate HLA molecule.
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 19 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01917708
Start Date
January 1 2014
End Date
September 19 2019
Last Update
December 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322